| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |